Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
CorrectionErratum

Correction to “A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor ɣ with Excellent Effect on Insulin Resistance and Type 2 Diabetes”

Journal of Pharmacology and Experimental Therapeutics January 2022, 380 (1) 90-91; DOI: https://doi.org/10.1124/jpet.115.223107err
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

In the above article [Liu H-J, Zhang C-Y, Song F, Xiao T, Meng J, Zhang Q, Liang C-L, Li S, Wang J, Zhang B, Liu Y-R, Sun T, and Zhou H-G (2015) J Pharmacol Exp Ther 353: 573-581 DOI: https://doi.org/10.1124/jpet.115.223107], the authors discovered a couple of mistakes were accidentally introduced during the preparation of Figs. 7 and 8. These errors do not change the results and conclusions of the paper.

In Fig. 7B, there was an error in the experimental group annotation. The Normal control should be diabetic control, and the diabetic control should be pioglitazone-30. Revised Fig. 7 is provided below:

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

In Fig. 8A, we found that A3 and A4 are all from the pioglitazone group. So we deleted one of the pictures of pioglitazone and added the picture of MDCCCL1636 group. And the revised figure was as below:

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

The HTML and PDF versions of the article have been corrected.

The authors regret this error and apologize for any inconvenience this may have caused.

  • Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 380 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 380, Issue 1
1 Jan 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correction to “A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor ɣ with Excellent Effect on Insulin Resistance and Type 2 Diabetes”
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
CorrectionErratum

Correction to “A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor ɣ with Excellent Effect on Insulin Resistance and Type 2 Diabetes”

Journal of Pharmacology and Experimental Therapeutics January 1, 2022, 380 (1) 90-91; DOI: https://doi.org/10.1124/jpet.115.223107err

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
CorrectionErratum

Correction to “A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor ɣ with Excellent Effect on Insulin Resistance and Type 2 Diabetes”

Journal of Pharmacology and Experimental Therapeutics January 1, 2022, 380 (1) 90-91; DOI: https://doi.org/10.1124/jpet.115.223107err
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Correction to “Protective Effect of Anwulignan on Gastric Injury Induced by Indomethacin in Mice”
  • Correction to “Interactive Effects of µ-Opioid and Adrenergic-α2 Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine”
  • Correction to “Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats”
Show more Erratum

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics